How can cardiologists take the lead in moving AI forward

Objectives of the CRT meeting

To establish a comprehensive and actionable roadmap for the trustworthy implementation of AI into clinical practice within cardiology, ensuring that AI tools are reliable, evidence-based, and contribute to improved patient outcomes. This roadmap will be developed through collaboration between the medical industry, regulators, notified bodies, professional societies, policy makers, payers and patient representatives. Insights and findings from the meeting will be summarized and distributed via academic publications including a white paper and industry reports.

Objectives of the 2nd CRT on AI meeting:

• Define how the cardiologists/ health professional can transition from a reactive position to a proactive role to lead the development of AI?
• To create a platform to bring together diverse expertise, spark innovation, and create actionable plans to move the field of AI in cardiology forward
• To Identify and address critical challenges in advancing AI applications development and implementation in cardiology

Objectives of the 2nd CRT on AI meeting:

• Presentation of four projects to be launched and accomplished in one year.

Programme

Day 1:  26 March 2025  11:30–19:15 CEST

SESSION 1 (11:30-15:50) Moderated by: Ruben Casado Arroyo and Katarzyna Markiewicz (Philips)

• 11:30-11:35 - Welcome from the CRT Chairpersons by Alexandra Goncalves (BMS) and Cecilia Linde
• 11:35-11:45 - Summary of the previous meeting on AI by Ruben Casado Arroyo and Katarzyna Markiewicz (Philips)
• 11:45-12:00 - Agenda overview and expected outcomes by Guy Spigelman (Amazon Web Services) & meeting facilitator, Folkert Asselbergs
• 12:10-12:30 - What are the requirements for evidence generation of AI models to be guideline proof? by Rohan Khera
• 12:30-13:30 - Buffet Lunch
• 13:30-14:30 - BREAKOUT SESSIONS: Brainstorm on ideas of project to be developed to improve clinical practices with AI (goal 10 to 15 ideas to be presented)
  • Group 1: What Projects can the ESC Launch to accelerate the adoption of AI? Lead: Enrico Caiani, Rapporteur: Alan Fraser
  • Group 2: What projects can the ESC Launch to empower clinicians with AI? Lead: Carlos Pena Gil, Rapporteur: Philip Moons
  • Group 3: What projects can the ESC launch to empower patients with AI? Lead: Gerhard Hindricks, Rapporteur: Andre Ziegler (Roche)
  • Group 4: What projects can the ESC launch to facilitate collaboration between industry and clinicians around the use of AI? Lead: Panos Vardas, Rapporteur: Sarah Adams (Alnylam)
• 14:30-14:40 - Report from breakout session 1 by Rapporteur: Alan Fraser
• 14:40-14:50 - Report from breakout session 2 by Rapporteur: Philip Moons
• 14:50-15:00 - Report from breakout session 3 by Rapporteur: Andre Ziegler (Roche)
• 15:00-15:10 - Report from breakout session 4 by Rapporteur: Sarah Adams (Alnylam)
• 15:10-15:50 - PANEL DISCUSSION and NEXT STEPS
• 15:50-16:20 - Coffee Break

SESSION 2 (16:20-19:00) Moderated by: Folkert Asselbergs and Alexandra Goncalves (BMS)

• 16:20-16:35 - Usability by design requirements to enable seamless integration of AI into clinical workflows. The experience of EPIC by John Rozier (EPIC)

• 16:35-16:50 - Guidance for Clinical Trial design for evaluation of GenAI by Spiros Denaxas (by Zoom)

• 16:50-17:05 - EMA view on regulation, what will be the next steps to adopt AI in clinical practice by Florian Lasch EMA (by Zoom)

• 17:05-17:45 - BREAKOUT SESSIONS: What mechanisms from the ESC perspectives should exist to ensure successful implementation of AI? (selection of the best idea per group to develop)

  • Group 1: What Projects can the ESC Launch to accelerate the adoption of AI? Lead: Enrico Caiani, Rapporteur: Alan Fraser
  • Group 2: What projects can the ESC Launch to empower clinicians with AI? Lead: Carlos Pena Gil, Rapporteur: Philip Moons
  • Group 3: What projects can the ESC launch to empower patients with AI? Lead: Gerhard Hindricks, Rapporteur: Andre Ziegler (Roche)
  • Group 4: What projects can the ESC launch to facilitate collaboration between industry and clinicians around the use of AI? Lead: Panos Vardas, Rapporteur: Sarah Adams (Alnylam)

• 17:45-17:55 - Report from breakout session 1 by Rapporteur: Alan Fraser

• 17:55-18:05 - Report from breakout session 2 by Rapporteur: Philip Moons

• 18:05-18:15 - Report from breakout session 3 by Rapporteur: Andre Ziegler (Roche)

• 18:15-18:25 - Report from breakout session 4 by Rapporteur: Sarah Adams (Alnylam)

• 18:25-19:00 - PANEL DISCUSSION and NEXT STEPS

• END OF DAY 1

Day 2:  27 March 2025  08:30–12:30 CEST

• 08:30-08:40 - Summary of day 1 by Folkert Asselbergs and Rodolphe Katra (Medtronic)
• 08:40–12:30 - SESSION 2.1: Bridging the Gap Between Research, Regulation and Commercialization, moderated by Cecilia Linde and Rodolphe Katra (Medtronic)
• 08:40-08:55 - Ecosystem development for responsible AI implementation by Markus Vogel (Microsoft)
• 08:55-09:10 - Assessment criteria supporting implementation and reimbursement of responsible AI systems (incl. HTA Labs) by Emily Eaton Turner (NICE)
• 09:10-09:25 - How to ensure trustworthiness in AI for healthcare: FUTURE-AI guidelines by Karim Lekadir
• 09:25-09:45 - Coffee Break
• 09:45-10:30 - BREAKOUT SESSIONS: Present your conclusions in 5 slides (Group Champions)
  • ESCquisite Trial, Rapporteur: Folkert Asselbergs
  • CARDIO-AI, Rapporteur: Sarah Adams (Alnylam)
  • PatientAI Crew, Rapporteur: Richard Stephens
  • ESCalate, Rapporteur: Fielder Camm
• 11:15-12:00 - PANEL DISCUSSION and NEXT STEPS
• 12:00-12:20 - Wrap-up, conclusions by Folkert Asselbergs and Rodolphe Katra (Medtronic)
• END OF DAY 2
• 12:30 - Buffet Lunch and Departures